Information de reference pour ce titreAccession Number: | 00007469-200436110-00009.
|
Author: | Dahl, HELENA 1; Linde, ANNIKA 1; Strannegard, ORJAN 2
|
Institution: | (1)From the Swedish Institute for Infectious Disease Control, Stockholm, Sweden (2)Department of Clinical Virology, Goteborg University, Goteborg, Sweden
|
Title: | In vitro inhibition of SARS virus replication by human interferons.[Article]
|
Source: | Scandinavian Journal of Infectious Diseases. 36(11-12):829-831, 2004.
|
Abstract: | Four different types of human interferon, interferon-[beta] (IFN-[beta]), recombinant IFN-[alpha]2a and IFN-[alpha]2b and natural IFN-[alpha] were tested for antiviral activity against SARS-coronavirus. The experiments were performed using in vitro cultivated monkey Vero E6 cells. IFN-[beta] was found to be the most highly active antiviral agent, followed by natural IFN-[alpha], whereas the 2 recombinant IFN-[alpha]2 species were poorly active in the system used. These results suggest that IFN-[beta] as well as natural IFN-[alpha] may be used for the treatment of SARS.
(C) 2004 Taylor & Francis Health Sciences
|
References: | 1. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 52: 2003; 715-20.
2. Stroher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F et al. Severe acute respiratory syndrome-related coronavirus is inhibited by Interferon-[alpha]. J Infect Dis 189: 2004; 1164-7.
3. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290: 2003; 3251-3.
4. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet 362: 2003; 293-4.
5. Tan ELC, Ooi EE, Lin CY, Tan HC, Lig AE, Lim B, Stanton LW. Inhibition of SARS-coronavirus infection in vitro with clinically approved anti-viral drugs. Emerging Inf Dis 10: 2004; 581-6.
6. Spiegel M, Pichlmair A, Muhlberger E, Haller O, Friedemann W. The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxS protein. J Clin Vir 30: 2004; 211-213.
7. Zheng B, He ML, Wong KL, Lum CT, Poon LL, Peng Y et al. Potent inhibition of SARS-associated coronavirus (SCOC) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma). J Interferon Cytokine Res 24: 2004; 388-90.
8. Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW et al. In vitro susceptibility of 10 clinical isolates of SARS-coronavirus to selected antiviral compounds. J Clin Virol 31: 2004; 69-75.
9. Elmen J, Wahlestedt C, Brytting M, Wahren B, Ljungberg K. SARS virus inhibited by siRNA. Precinica 2: 2004; 135-42.
10. Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS-coronavirus infection in macaques. Nat Med 10: 2004; 290-3.
11. Ferreira PC, Peixoto MLP, Silva MAV, Golgher RR. Assay of human interferon in Vero cells by several methods. J Clin Microbiol 9: 1979; 471-5.
12. Weck PK, Apperson S, Stebbing ML. Comparison of the antiviral activities of various cloned human interferon-alpha subtypes in mammalian cell cultures. J Gen Virol 57: 1981; 233-7.
13. Tonew M, Gluck B. Interferon sensitivity of various cell lines. J Basic Microbiol 26: 1986; 173-9.
14. Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DA. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother 24: 1983; 713-5.
15. Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J Infect Dis 154: 1986; 443-7.
16. 16. Foster GR, Finter NB. Are all type 1 human interferons equivalent?. J Viral Hepatitis 5: 1998; 143-52.
|
Language: | English.
|
Document Type: | Original Article.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0036-5548
|
NLM Journal Code: | ucx, 0215333
|
Annotation(s) | |
|
|